Abstract: Pharmaceutical compositions, methods of administration, and methods of treatment of cancer with new generation taxoids, of formulas (I) and (II), and derivatives thereof, are described:

Abstract: The present invention relates to novel intermediates for the hemisynthesis of taxanes and to their processes of preparation. The compounds of the present invention include precursor compounds of taxane side chains.

Abstract: 9-dihydro-13-acetylbaccatin III, one of the chemicals obtained from Taxus canadensis is used to produce, inter alia, 10-decetylbaccatin III, a useful intermediate for the preparation of paclitaxel and analogues thereof The 9-dihydro-13-acetylbaccatin III is converted into the 10-deacetylbaccatin III by a simple three step process involving (a) replacement of the C-7 hydroxyl group of tho 9-dihydro compound with a protecting group, (b) the oxidizing of the C-7 protected compound to produce a C-9 ketone, and (c) the deprotecting of the C-9 ketone to produce 10-deacetylbaccatin III.

Abstract: Taxane derivatives having alternative C9 substituents.

Abstract: Taxane derivatives having an alkoxy, alkenoxy or aryloxy substituted C13 side chain.

Abstract: Novel oxazolidines finding utility as intermediates in the preparation of C-13 acyloxy sidechain-bearing taxanes such as paclitaxel and analogs thereof. The present invention also relates to novel methods of coupling the oxazolidines to form the aforementioned taxanes, and to methods of preparing the oxazolidines.

Abstract: Taxanes having a carbonate substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: The present invention provides a process for synthesizing 3-fluoroalkoxymethyl-3-alkyloxetanes, suitable as intermediates for preparing various fluorine-containing functional materials, represented by General Formula (Ia): wherein, X1 and X2 independently represent hydrogen or fluorine; Rf represents fluorine or C1-C18 linear or branched perfluoroalkyl; and R represents methyl, ethyl, n-propyl or isopropyl.

Abstract: Improved polymer-immobilized photosensitizer are disclosed as well as methods of preparing and using them. The polymer-immobilized photosensitizers comprise a cross-linked polymer backbone, a plurality of cationic ammonium or phosphonium groups covalently bound to the polymer backbone and an immobilized photosensitizer. The average total number of carbon atoms in the ammonium or phosphonium group is at least four and preferably at least 12. The photosensitizer can be either covalently or ionically bound to the polymer. Polymer-supported photosensitizers of the invention are unexpectedly superior in catalyzing the photosensitized oxidation of compounds containing carbon-carbon double bonds.

Abstract: A process for the preparation of paclitaxel starting from 10-deacetylbaccatine III.

Abstract: This invention is directed to novel halogenated paclitaxel derivatives, processes for their preparation and use as effective anti-tumor agents.

Abstract: Taxane derivatives having alternative C7 substituents.

Abstract: Disclosed is a process for isolating and purifying paclitaxel from a natural resource of taxanes, comprising the steps of (a) washing a raw material comprising paclitaxel with water in order to remove soluble impurities from the raw material; (b) extracting with an organic solvent a wet raw material comprising paclitaxel; (c) contacting the wet raw material with a salt to obtain a biomass by precipitation, isolation, and drying; (d) removing resin and natural pigments from the dried biomass by dissolving the biomass in acetone or an acetone-hexane mixture, and adding at least one polar solvent until a paclitaxel-enriched oil phase is obtained; and (e) chromatography purifying the paclitaxel-enriched oil phase in a volatile solvent to obtain a purified solution, followed by crystallization.

Abstract: These compounds contain an oxetane functionality and a cinnamyl functionality. The oxetane functionality is homopolymerizable in reactions that can undergo cationic or anionic ring opening, and the cinnamyl functionality is polymerizable with compounds such as electron acceptor compounds. The dual functionality allows for dual cure processing. The generic structure of such compounds is in which R is a methyl or ethyl group, X and Y independently are a direct bond, or an ether, ester, or carbamate group, and Q is a divalent hydrocarbon (which may contain heteroatoms of N, O, or S), provided that X and Y will not both be direct bonds in the same molecule.

Abstract: An antitumor compound of formula (5): Also provided by the present invention is a method of preparing a compound of formula (5) whereby diesterification of the alcohol groups located at the 2′ and 7 positions of paclitaxel is followed by the hydrolysis of the 2′ hexanoate group resulting in 7-hexanoyltaxol.

Abstract: The present invention concerns novel taxane derivatives, their use as antitumor agents, and pharmaceutical formulations. The invention claims compounds of formula I and the use of compounds of formula I or pharmaceutical salts thereof as oral drugs for the treatment of human or veterinary disease. in which: R is phenyl, isopropyl, or tert butyl; R1 is —C(O)Rz in which Rz is (CH3)3CO—, (CH3)3CCH2—, CH3(CH2)3O—, cyclobutyl-, cyclohexyloxy, or (2-furyl); R2 is CH3C(O)O—.

Abstract: Taxanes having a carbamoyloxy substituent at C(7), a hydroxy substituent at C(10, and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: Process for the preparation of a derivative or analog of baccatin III or 10-desacetyl baccatin III having a C2 substituent other than benzoate and/or a C4 substituent other than acetate in which the C2 benzoate substituent and/or the C4 acetate substituent of a derivative of baccatin III or 10-desacetyl baccatin III is/are selectively reduced to the corresponding hydroxy group(s) and converted to R7COO— and/or R8COO—, respectively, wherein R7 and R8 are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C8 alkynyl, moncyclic aryl, or monocyclic heteroaryl.

Abstract: Process for the preparation of a derivative or analog of baccatin III or 10-desacetyl baccatin III having a C9 substituent other than keto in which the C9 keto substituent of taxol, a taxol analog, baccatin III or 10-desacetyl baccatin III is selectively reduced to the corresponding hydroxy group.

Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.

Abstract: Processes for the preparation of taxol and other taxanes through selective derivatization of the C(7) and C(10) hydroxyl groups of 10-DAB, particularly a novel process using a new strategy in which the C(10) hydroxyl group is protected or derivatized prior to the C(7) hydroxyl group; and the provision of C(7) and C(10) derivatized 10-DAB compounds.

Abstract: A process for preparing N-acyl, N-sulfonyl and N-phosphoryl substituted isoserine esters in which a metal alkoxide is reacted with a &bgr;-lactam.

Abstract: N-deacetyl-thiocolchicine and 10-deacetyl-baccatin III derivatives of formula (I) wherein R and n have the meanings specified in the disclosure, are valuable antitumoral drugs.

Abstract: This invention is to provide a novel taxol derivative useful as an antitumor compound having respective substituent groups, represented by the following formula (I) which can be orally administered

Abstract: Taxanes having a heterosubstituted acetate substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: The present invention provides a process for synthesizing 3-fluoroalkoxymethyl-3-alkyloxetanes suitable as intermediates for preparing various fluorine-containing functional materials, the process comprising using 3-alkyloxetane methanol as a starting compound and adding the compound to a fluoroolefin in the presence of an alkali.

Abstract: A process for preparing compounds of formula (I) comprising radical addition of RfI to 3-(allyloxy)methyl-3-alkyloxetane (1) wherein R is C1-3 alkyl and Rf is C1-18 linear or branched fluoroalkyl. The compounds of formula (I) are useful as intermediates for preparing various fluorine-containing functional materials.

Abstract: Taxanes having a heterosubstituted acetate substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: Taxanes having a carbonate substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: New photopolymerizable liquid crystalline dioxetane compounds are provided having the general formula I: wherein R1 and R2 are independently selected from straight or branched C1-C4 alkyl and hydrogen; X and X′ are independently selected from oxygen, sulfur, a single covalent bond, —O—CO—, —CO—O—, and —O—CO—O—; Y and Y′ are spacer groups having each independently 1 to 30 carbon atoms (linear or branched), in which the carbon chain may be interrupted by oxygen in the ether function or by sulfur in the thioether function; Z and Z′ are independently selected from oxygen, sulfur, a single covalent bond, —O—CO—, —CO—O—, and —O—CO—O—; and M is any suitable mesogenic group. Also, compositions are provided containing one or more compounds of formula I, as well as methods of preparing said compounds and compositions.

Abstract: The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix.

Abstract: A process for preparing N-acyl, N-sulfonyl and N-phosphoryl substituted isoserine esters in which a metal or an ammonium alkoxide is reacted with a &bgr;-lactam.

Abstract: Taxane derivatives having alternative C2 substituents.

Abstract: Methods of preparing amino acid-substituted taxanes such as: using selected blocked amino acids are disclosed. After coupling of the blocked amino acid to the taxane, deprotection is carried out with about an equimolar amount of a secondary amine thus substantially avoiding base-catalyzed hydrolysis of amino acid from the taxane. The preferred amino acid-taxanes are useful as intermediates in the production of polymer conjugated therapeutic compositions or as part of pharmaceutically acceptable formulations.

Abstract: Taxanes having an ester substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: Monofunctional polyfluorooxetane oligomers, polymers, and copolymers are prepared by the cationic polymerization of fluorooxetane monomers with a monoalcohol. In addition to serving as an initiator, the monoalcohol can also serve as a solvent for the fluorooxetane or other monomers to produce oligomers, polymers, or copolymers having low cyclic content. Suitable comonomers generally include various cyclic ethers. The polyfluorooxetane oligomer, polymer, or copolymer having a single hydroxyl end group can be functionalized with a variety of compounds so as to yield a functional end group such as an acrylate, a methacrylate, an allylic, an amine, etc., with the functionalized oligomer or polymer being suitable for use in radiation curable or thermal curable coating compositions. These functionalized polymers can be copolymerized and cured to provide improvements in wetting and surface properties.

Abstract: Methods for obtaining taxanes from novel sources are disclosed. Angiosperms other than hazelnut and the gymnosperm ginkgo have been discovered to be sources of taxane, including paclitaxel. Taxane may also be obtained from fungal endophytes from these plants. Methods for optimizing the recovery of taxane from plant sources are disclosed in which a plant part is surface-sterilized before extracting taxane therefrom or before culturing fungal endophytes therefrom.

Abstract: Compounds according to formula I: T1—L—T2   (I), wherein T1 is a taxoid group, preferably of Formula II: wherein R1 is C6H5; R2 is O; L is a linking group; and T2 is a substituent selected from the group consisting of epipodophyllotoxin, amsacrine, ellipticine, anthracycline antibiotic, mitoxantrone, and colchicine groups, and pharmaceutically acceptable salts thereof, are provided herein. The compounds are useful in, among other things, treating tumors or cancer in subjects in need thereof, inducing cellular differentiation, and inhibiting cellular mitosis.

Abstract: Taxanes having an ester substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: Taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.

Abstract: A cytotoxic agent comprising one or more polyethylene glycol-containing taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more polyethylene glycol-containing taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more polyethylene glycol-containing taxanes linked to a cell binding agent.

Abstract: This invention relates to a method for preparing taxane derivatives of general formula (I) by esterification at a temperature between −10 and 60° C. of a derivative of baccatine III or 10-deacetyl baccatine III of general formula (II) by means of an acid of general formula (III), followed by replacement of the protective groupings G1, G2 and R2 of the resulting product by hydrogen atoms. In formulae (I), (II) or (III), Ar stands for an aryl radical; R stands for hydrogen or acetyl; R1 is benzoyl or ter.butoxycarbonyl; G1 is a hydroxy function protective grouping, G2 stands for the acetyl radical or a hydroxy function protective grouping, and R2 stands for a hydroxy function protective grouping.

Abstract: Seco-baccatin III derivatives of formula: wherein R, R1-R4, R1, R11, and R111 are disclosed herein; pharmaceutical compositions comprising seco-baccatin III derivative; and methods for treating cancer, arthritis, and inhibiting angiogenesis in an animal comprising administering to a patient in need thereof a therapeutically effective amount of a seco-baccatin III derivative are disclosed.

Abstract: The present invention relate to a method to increase the production level of paclitaxel by changing the temperature during the plant cell culture. According to the present invention, the production of the paclitaxel comprises the following procedure: (i) cultivating the Taxus genus plant cells in a medium at ca. 20 to 25° C.; and (ii) when growth of the plant cells has progressed sufficiently, changing the cultivation temperature to ca. 26 to 32° C. to continue the culture. The present invention comprises also the method of increasing the paclitaxel production by inoculating the cells at a high initial concentration and by increasing the saccharide concentration in the medium: According to the present invention, paclitaxel can be mass-produced conveniently and therefore has an industrial application.

Abstract: The present invention relates to a semi-synthetic process to convert a naturally occurring taxane into a suitable starting material for the synthesis of paclitaxel and related compounds. Specifically, the present invention relates to a process for the conversion of 9-dihydro-13-acetylbaccatin III into a 7-protected baccatin III which can then be used as starting material for the synthesis of taxane derivatives such as paclitaxel, docetaxel, cephalomannine and other taxanes structurally related to baccatin III. The method as described uses a preparative scale technique which is amenable to commercial scale-up.

Abstract: Taxane derivatives having alternative C10 substituents.

Abstract: 1-Deoxybaccatin III, 1-deoxytaxol and 1-deoxy taxol analogs and method for the preparation thereof.

Abstract: Taxane prodrugs comprise a taxane joined by a hydrolyzable bond to one or more oligomers that comprise a polyethylene glycol moiety. The oligomer preferably further comprises a salt-forming moiety.

Abstract: The present invention provides a novel semi-synthetic method of producing a variety of novel taxane derivatives. The method involves the reaction of a phenylisoserine derivative with a suitably blocked Baccatin III derivative to produce a taxane substrate that may be further modified to form Pactitaxel and other potentially useful taxane derivatives.

Abstract: Taxane derivatives having an alkyl substituted C13 side chain.